These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31409550)

  • 1. Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.
    O'Reilly D
    Clin Genitourin Cancer; 2019 Oct; 17(5):e886-e887. PubMed ID: 31409550
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.
    Mark M; Klingbiel D; Mey U; Winterhalder R; Rothermundt C; Gillessen S; von Moos R; Pollak M; Manetsch G; Strebel R; Cathomas R
    Clin Genitourin Cancer; 2019 Apr; 17(2):e323-e328. PubMed ID: 30686756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2016 Jul; 196(1):103. PubMed ID: 27321503
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Conteduca V; Lolli C; De Giorgi U
    Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
    [No Abstract]   [Full Text] [Related]  

  • 8. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Xu S; De Porre P
    Clin Pharmacokinet; 2017 Feb; 56(2):213-214. PubMed ID: 27815867
    [No Abstract]   [Full Text] [Related]  

  • 14. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
    J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Srinivas NR
    Clin Pharmacokinet; 2017 Feb; 56(2):211-212. PubMed ID: 27815866
    [No Abstract]   [Full Text] [Related]  

  • 18. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
    Lin J; Patel SA; Sama AR; Hoffman-Censits JH; Kennedy B; Kilpatrick D; Ye Z; Yang H; Mu Z; Leiby B; Lewis N; Cristofanilli M; Kelly WK
    Oncologist; 2016 Nov; 21(11):1296-1297e. PubMed ID: 28178640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Rescigno P; de Bono JS
    Eur Urol; 2016 Dec; 70(6):e170-e171. PubMed ID: 27240941
    [No Abstract]   [Full Text] [Related]  

  • 20. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
    Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
    J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.